Mast Therapeutics Inc (NYSEMKT:MSTX) And Savara Update On Expected Merger Exchange Ratio

0
2079

Savara Inc. and Mast Therapeutics Inc (NYSEMKT:MSTX) reported the expected exchange ratio computed under the January 6, 2017 merger deal. Upon closure of the merger deal, each due share of Savara common stock will be converted into the right to get 0.5860 of a share of MSTX after adjusting for reverse stock split.

The details

The exchange ratio is dependent on each party’s existing capitalization and Mast’s projected net cash as of the probable closing date. The company’s current capitalization is dependent on a projected reverse stock split of 1 share of MSTX for every 70 shares of MSTX.

Depending on the expected exchange ratio, after the merger, current Savara stockholders are projected to own in the aggregate almost 77% of the combined firm, and current Mast stockholders are expected to own almost 23% of the combined firm. The exchange ratio can be adjusted depending on any changes to each company’s capitalization before closing.

The major factors behind the reverse stock split process is to increase the stock price to a mark that meets the guidelines for listing and is within more of a normal trading price among firms listed on Nasdaq platform, and to ensure Mast will have an adequate amount of approved and unissued common stock to close the merger deal.

Mast reported that the reverse stock split will not have any immediate impact on the aggregate market value of its stock, or any shareholder’s ownership in the firm, but may offer long-term benefits to the combined firm and its shareholders.

The changed share price will likely expand the pool of potential shareholders into the firm by meeting guidelines of certain institutional shareholders who have internal policies barring them from buying stocks below a specific minimum share price, achieving requirements of certain financial experts who have policies to disappoint their customers from investing into such equities, and making the firm eligible for addition in certain biotech indices.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.